Wanbond announced that the wholly-owned subsidiary Wanbond Pharmaceutical Group Co., Ltd. has recently completed a phase II/III key registration clinical trial of the new drug huxerine A controlled-release tablets for the treatment of mild and moderate Alzheimer's dementia, and recently completed the enrollment of 50 subjects. Huperzine A controlled-release tablets are a Class 2.2 new drug independently developed by the company to treat mild and moderate Alzheimer's dementia. It uses biphasic controlled release technology to smooth the peak and valley curve of drug release and prolong the release time of the drug in the body, thereby achieving rapid efficacy, reducing adverse reactions, and improving dosage and safety. At the same time, controlled release technology supports dosing once a day, improving patients' convenience and long-term adherence.

Wanbond announced that the wholly-owned subsidiary Wanbond Pharmaceutical Group Co., Ltd. has recently completed a phase II/III key registration clinical trial of the new drug huxerine A controlled-release tablets for the treatment of mild and moderate Alzheimer's dementia, and recently completed the enrollment of 50 subjects. Huperzine A controlled-release tablets are a Class 2.2 new drug independently developed by the company to treat mild and moderate Alzheimer's dementia. It uses biphasic controlled release technology to smooth the peak and valley curve of drug release and prolong the release time of the drug in the body, thereby achieving rapid efficacy, reducing adverse reactions, and improving dosage and safety. At the same time, controlled release technology supports dosing once a day, improving patients' convenience and long-term adherence.